Avion to include Quatrefolic as part of Prenate portfolio

Avion Pharmaceuticals LLC this week announced that it has fortified its partnership with Gnosis S.P.A. by agreeing to make Quatrefolic part of its Prenate prescription prenatal vitamin portfolio.

The terms of the agreement state that Avion will provide Quatrefolic through 2028, when its patent life expires.

"Avion is proud to support our community of moms and babies with prescription nutritional support that meet the highest standards for pregnancy and breastfeeding," Mike Sullivan, president of Avion, said. "This important partnership with Gnosis, S.P.A., allows Prenate to demonstrate our commitment to both our prescribers and our women's health care communities with the gold standard in bioavailable folate".

Quatrefolic is a type of folate designed to be an important part of prenatal nutrition in support of expectant mothers and women who are attempting to conceive. Folic acid can aid in the prevention of neural tube defects (NTD), including spina bifida. Approximately half of women in the United States have MTHFR polymorphism, which prevents the body from metabolizing folic acid gained through diet or nutritional supplements.

Available in Prenate prescription prenatals, Quatrefolic is already in a biologically active form for the body to absorb when it is administered to patients. This allows it to overcome MTHFR polymorphism.